Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
687 articles with Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team
Shares of Alexion Pharmaceuticals have jumped nearly 5% after the company’s board of directors rejected a push for a sale of the company from one of its largest stakeholders, U.K.-based Elliott Advisors, Ltd.
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.
Alexion Pharmaceuticals announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five scientific data presentations from the company’s complement program will be showcased during the annual meeting of the American Society of Hematology (ASH) in Orlando, Fla., from Dec. 7 to 10, 2019.
Alexion Pharmaceuticals, Inc. announced financial results for the third quarter of 2019.
Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response
Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for Factor D inhibition in additional alternative pathway complement-mediated rare diseases
The deal is expected to close in the first half of 2020.
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the company’s first Chief Corporate Affairs Officer
Following the release of the financial results, Alexion management will conduct a conference call and audio webcast at 8:00 a.m. Eastern Time
There are several scheduled PDFUA dates for the U.S. Food and Drug Administration over the next two weeks. Here’s a look.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (NASDAQ:EIDX) today announced an agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan.
Alexion Pharmaceuticals announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET.
Alexion Pharmaceuticals announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET.
Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) have been accepted for presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11 to 13, 2019.
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.